South Korea Gene Therapy Market Size & Outlook, 2023-2030
The gene therapy market in South Korea is expected to reach a projected revenue of US$ 9.6 million by 2030. A compound annual growth rate of 5.7% is expected of South Korea gene therapy market from 2024 to 2030.
The South Korea gene therapy market generated a revenue of USD 6.5 million in 2023 and is expected to reach USD 9.6 million by 2030.
The South Korea market is expected to grow at a CAGR of 5.7% from 2024 to 2030.
In terms of segment, lentivirus was the largest revenue generating vector type in 2023.
Lentivirus is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
Market revenue in 2023
USD 6.5 million
Market revenue in 2030
USD 9.6 million
Growth rate
5.7% (CAGR from 2024 to 2030)
Largest segment
Lentivirus
Fastest growing segment
Lentivirus
Historical data
2018 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Lentivirus, AAV
Key market players worldwide
Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc
Other key industry trends
In terms of revenue, South Korea accounted for 0.1% of the global gene therapy market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Asia Pacific, Japan gene therapy market is projected to lead the regional market in terms of revenue in 2030.
Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 246.2 million by 2030.
South Korea is the 12th largest market in the healthcare industry. The South Korean government has planned to invest more than USD 1.7 billion in the country's biotechnology and biopharmaceutical sector.
The country is one of the key markets for regenerative medicine as it was the first to commercialize stem cell therapy. The Korean government is also supportive of the adoption of gene therapy products.
For instance, in 2019, the government passed the Act on the Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals, which allows conditional approval for the commercial sale of phase II completed drugs.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Lentivirus was the largest segment with a revenue share of 50.77% in 2023.
Horizon Databook has segmented the South Korea gene therapy market based on lentivirus, aav covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea is the 12th largest market in the healthcare industry. The South Korean government has planned to invest more than USD 1.7 billion in the country's biotechnology and biopharmaceutical sector.
The country is one of the key markets for regenerative medicine as it was the first to commercialize stem cell therapy. The Korean government is also supportive of the adoption of gene therapy products.
For instance, in 2019, the government passed the Act on the Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals, which allows conditional approval for the commercial sale of phase II completed drugs.
South Korea Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
Lentivirus
AAV
RetroVirus & gamma RetroVirus
Modified Herpes Simplex Virus
Adenovirus
Non-viral Plasmid Vector
Other Vector Type
South Korea Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Large B-cell Lymphoma
ADA-SCID
Melanoma (lesions)
Beta-Thalassemia Major/SCD
Head & Neck Squamous Cell Carcinoma
Peripheral arterial disease
Spinal Muscular Atrophy (SMA)
Others
Reasons to subscribe to Gene Therapy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.